Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: NK/T-cell Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) and Takeda. The supporters have no influence over the production of the content.

Welcome to The NK/T-Cell Lymphoma Channel

VJHemOnc brings you all of the latest news in the field of NK/T-cell lymphoma, as presented by top experts. The NK/T-Cell Lymphoma Channel covers all of the state-of-the-art updates in NK/T-cell lymphoma from international congresses, including video interviews on presentations and abstracts, podcasts, and roundtable discussions with key opinion leaders.

Explore The NK/T-Cell Lymphoma Channel to learn about the latest advances in the field, including the use of novel therapies and combination regimens, and research identifying prognostic biomarkers.

View Aggressive T-Cell & NK-Cell Lymphoma Overview Page
The risk of T-cell malignancies associated with CAR T-cell therapy 2:20
The risk of T-cell malignancies associated with CAR T-cell therapy
Yi Lin • 9 Dec 2023
DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL 1:11
DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL
Won-Seog Kim • 16 Jun 2023
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase 2:15
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase
Christian Gisselbrecht • 25 Apr 2023
IMC-001: preliminary results of novel PD-L1 inhibitor for R/R extranodal NK/T cell lymphoma 2:04
IMC-001: preliminary results of novel PD-L1 inhibitor for R/R extranodal NK/T cell lymphoma
Won-Seog Kim • 24 Nov 2022
Approaching NK/T-cell lymphoma 0:42
Approaching NK/T-cell lymphoma
Won-Seog Kim • 11 Jun 2022
Results of Phase II study of tislelizumab in R/R NK/T-cell neoplasms 1:15
Results of Phase II study of tislelizumab in R/R NK/T-cell neoplasms
Emmanuel Bachy • 11 Jun 2022
Advances in treating T-cell lymphoma 3:56
Advances in treating T-cell lymphoma
Franco Cavalli • 24 Jun 2021
Advances in extranodal natural killer/T-cell lymphoma 8:54
Advances in extranodal natural killer/T-cell lymphoma
Qing-qing Cai • 24 Jun 2021
EGR1 as a prognostic biomarker in ENKTL 1:07
EGR1 as a prognostic biomarker in ENKTL
Won-Seog Kim • 21 Jun 2021
Novel issues in the combined modality treatment of lymphomas 2:55
Novel issues in the combined modality treatment of lymphomas
Lena Specht • 14 Jun 2017
An overview on NK/T-cell lymphoma treatment 1:58
An overview on NK/T-cell lymphoma treatment
Won-Seog Kim • 14 Jun 2017

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) and Takeda.

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals